small molecule

KHINDIVI

HYDROCORTISONE

Loss of exclusivityFebruary 2043latest FDA-listed patent expiry
CompanyEton PharmaceuticalsSee this company's full patent-cliff portfolio

Drug detail

Brand nameKHINDIVI
Active ingredientHYDROCORTISONE
Strength1MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2025
Marketing statusRX

Listed patents

PatentExpiresType
12133914February 2043use U-4215
11904046February 2043product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KHINDIVI patent cliff — loss of exclusivity February 2043 | CliffBio